Search results
Results from the WOW.Com Content Network
Denosumab, sold under the brand name Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. [19] [20] The most common side effects are joint and muscle pain in the arms or legs. [21]
While men are less likely to develop osteoporosis, it is possible and has been occurring more often in recent years in men over age 65. “Most men should aim for 1,000 - 1,200mg of calcium per ...
Prolia, approved in 2010 to treat bone loss in postmenopausal women and later approved to treat men and women at high risk of fracture, brought in total third-quarter sales of $986 million.
Tamsulosin – ARISTO Pharma – 0.4 mg prolonged-release tablets – Urologikum. Tamsulosin, sold under the brand names including Flomax and Contiflo, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones.
Teriparatide is indicated for the treatment of postmenopausal women with osteoporosis; [13] for the increase of bone mass in men with primary or hypogonadal osteoporosis; [13] and treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.
Research suggests that approximately 40 percent of men over 45 have clinically low testosterone levels. Risk Factors for Testosterone Deficiency Risk factors for developing hypogonadism include:
The International Osteoporosis Foundation and the European Calcified Tissue Society recommend pharmacological therapy for osteoporosis in postmenopausal women and men ≥70 years, with a previous fragility fracture, or a dose equivalent of prednisone ≥7.5 mg daily for ≥3 months. For premenopausal women and men <50 years taking steroids for ...
Treatment of osteoporosis or non-malignant bone disease with denosumab (not taking systemic glucocorticoids) High: Patients being treated for osteoporosis or non-malignant bone disease with oral bisphosphonates/quarterly or yearly infusions of intravenous bisphosphonates for >5 years